Genmab Initiates Study of Zalutumumab with Radiotherapy in Head and Neck Cancer

Summary:  Genmab initiates a Phase I/II study of zalutumumab in combination with
radiotherapy for the treatment of advanced head and neck cancer.                

Copenhagen, Denmark; June 24, 2008 - Genmab A/S (OMX: GEN) announced today it   
has initiated a Phase I/II study of zalutumumab (HuMax-EGFr™) in combination    
with radiotherapy for the treatment of advanced head and neck cancer.  The study
will include a maximum of 36 patients who are ineligible for platinum based     
chemotherapy.                                                                   

“Platinum based chemotherapy is currently considered to be the best available   
standard treatment for advanced head and neck cancer.  We hope zalutumumab may  
some day provide a treatment option for patients who are in need of less toxic  
therapies,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.    

About the trial                                                                 
In the dose-escalation part of the study, 6 to 24 patients will be enrolled in  
cohorts of 3 patients per dose level of zalutumumab.  The dose level for each   
successive cohort will be determined by the aggregate safety data observed in   
the prior cohorts.  When the maximum tolerated dose of zalutumumab is           
established, an additional cohort of 12 patients will be enrolled and treated at
this level.                                                                     

Patients in the study will receive 8 weekly infusions of zalutumumab with the   
first cohort receiving an initial dose of 12 mg/kg of zalutumumab followed by 7 
maintenance doses of 8 mg/kg of zalutumumab in addition to radiotherapy.        
Patients will be evaluated at 4 weeks following the last dose of zalutumumab and
will be followed for a total of 2 years.                                        

The objective of the study is to evaluate the safety of repeat dosing and       
establish the maximum tolerated dose of zalutumumab in combination with         
radiotherapy in patients with advanced head and neck cancer who are ineligible  
for platinum based chemotherapy.  The primary endpoint of the study is adverse  
events.                                                                         


About Genmab A/S                                                                
Genmab is a leading international biotechnology company focused on developing   
fully human antibody therapeutics for unmet medical needs.  Using cutting-edge  
antibody technology, Genmab's world class discovery, development and            
manufacturing teams have created and developed an extensive pipeline of products
for potential treatment of a variety of diseases including cancer and autoimmune
disorders.  As Genmab advances towards a commercial future, we remain committed 
to our primary goal of improving the lives of patients who are in urgent need of
new treatment options.  For more information on Genmab's products and           
technology, visit www.genmab.com.                                               

This press release contains forward looking statements. The words “believe”,    
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify    
forward looking statements. Actual results or performance may differ materially 
from any future results or performance expressed or implied by such statements. 
The important factors that could cause our actual results or performance to     
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical   
trials including unforeseen safety issues, uncertainties related to product     
manufacturing, the lack of market acceptance of our products, our inability to  
manage growth, the competitive environment in relation to our business area and 
markets, our inability to attract and retain suitably qualified personnel, the  
unenforceability or lack of protection of our patents and proprietary rights,   
our relationships with affiliated entities, changes and developments in         
technology which may render our products obsolete, and other factors. Genmab is 
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to      
actual results, unless this is required by law.                                 

Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);  
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);   
HuMax-CD32b(TM) and UniBody(R) are all trademarks of Genmab A/S.                

Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M: 
+45 25 27 47 13, E: hth@genmab.com                                              
                                                                                
Stock Exchange Release no. 31/2008                                              

###